Global law firm Clifford Chance has acted as the international counsel to Star Sports Medicine Co., Ltd. (Star Sports Medicine) on its initial public offering and listing on the Main Board of The Stock Exchange of Hong Kong.
Partners Fang Liu and Virginia Lee co-led the transaction with support from partner of Clifford Chance (Beijing) Claire Cao. The wider deal team includes Yuhang Li, Yu’er Shao, Hardy Ye, Julie Luo and Ruiyi Chen.
Star Sports Medicine is China’s largest domestic provider of sports medicine implants and instruments, specializing in clinical sports medicine solutions that encompass sports medicine implants, active equipment, associated medical consumables and surgical instruments, as well as regenerative repair products. It offers holistic solutions for the treatment of soft tissue injuries to rotator cuffs, ligaments and meniscus across the shoulders, knees, hips, feet, ankles, elbows, hands and wrists, as well as for the rehabilitation and prevention of sports-related injuries.
Clifford Chance has a strong track record of advising on the Hong Kong listings of medical devices companies, most recently advising on the listing of Edge Medical.
